FDA warns of cardiac risk with stress test agents

FDA warns of cardiac risk with stress test agents

(HealthDay)—The use of cardiac nuclear stress test agents comes with a rare but serious risk of heart attack and death, according to a warning sent by the U.S. Food and Drug Administration to health care professionals.

Lexiscan (regadenoson) and Adenoscan (adenosine), used in cardiac stress tests in patients who cannot exercise adequately, help identify coronary artery disease by dilating heart arteries and increasing blood flow. The risk stems from reduced blood flow to obstructed areas, which may result in potentially fatal .

The FDA has approved drug label changes for the two drugs to highlight these risks and update recommendations for their use. At this time, it is not clear if there is any difference in risk between Lexiscan and Adenoscan.

According to the agency, should "screen all candidates for their suitability to receive Lexiscan or Adenoscan. Avoid using these drugs in patients with signs or symptoms of unstable angina or cardiovascular instability, as these patients may be at greater risk for serious cardiovascular adverse reactions."

More information: More Information

Related Stories

Recommended for you

Report urges major steps to help victims of cardiac arrest

date Jun 30, 2015

Would you know what to do if you see someone collapse, not breathing—a loved one at home, a co-worker at the office, a stranger on the street? Far too many Americans die of cardiac arrest, and now a major new report urges ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.